Clinical data demonstrates significantly increased cure rates using Resistance Guided Therapy for treating the STI Superbug M. genitalium
SpeeDx ResistancePlus® MG test supports new STI management guidelines
SYDNEY, Australia, June 21, 2018 (GLOBE NEWSWIRE) -- SpeeDx Pty. Ltd. today announced clinical data contained in a new study published in the June 2018 issue of Clinical Infectious Diseases 1 [link ] supports the use of Resistance Guided Therapy for more effective treatment of Mycoplasma genitalium infections. Using the SpeeDx ResistancePlus® MG test, the authors recorded an overall cure rate of >92%, a significant increase compared with previous cure rates of 67% prior to using Resistance Guided Therapy.ResistancePlus MG test simultaneously detects the sexually transmitted infection (STI) M. genitalium and the genetic markers linked to antimicrobial resistance (AMR).
The test is CE marked and in use across Europe, and available in laboratories across Australia and New Zealand. Clinical trials are underway in the U.S. in preparation for de novo clearance for the test with the U.S. Food and Drug Administration.
"This is a seminal publication demonstrating a remarkable improvement in treating what has essentially become an STI superbug," said Colin Denver, SpeeDx CEO. "Using diagnostics to define appropriate treatment decisions is key when dealing with the global health threat of antimicrobial resistance."
Senior study author Associate Professor Catriona Bradshaw has worked on M. genitalium for 15 years. "I've seen resistance to azithromycin, the frontline recommended treatment for M. genitalium infection, rise to over 50% in Melbourne over the last decade," she said. "Unfortunately, it's now a situation mirrored in many countries around the world."1
Within the context of high level resistance and ongoing use of azithromycin - which helps to further increase macrolide resistance - the team developed a three-tier treatment pathway. The first step was switching from azithromycin to doxycycline for initial treatment, and then using the ResistancePlus MG test to detect macrolide resistance biomarkers. If macrolide resistance was detected, patients were treated with a quinolone antibiotic (sitafloxacin) to avoid unnecessary and ineffective use of azithromycin. If macrolide resistance was not detected, the patient was given a higher than standard dose of azithromycin over 4 days to reduce the development of de novo resistance.
Importantly, using doxycycline for initial STI treatment reduces overall use of azithromycin and reduces bacterial load, which the authors hypothesise improves the effectiveness of subsequent macrolide or quinolone treatment. Ongoing work will evaluate the use of moxifloxacin rather than sitafloxacin following doxycycline, as this agent is more widely available.
Data from this study has already influenced recent STI management guideline updates in Australia2 and the United Kingdom3, with recommendations to use doxycycline upfront and to assess the resistance status of M. genitalium infections in order to guide appropriate treatment. Using diagnostics to define appropriate treatment decisions is in line with recent recommendations on global management of AMR.8 Resistance Guided Therapy results in a more effective use of antibiotics, curtails the use of inappropriate prescribing and helps preserve the use of key medicines needed to combat the global rise of antimicrobial resistance.
About M. genitalium
M. genitalium is a sexually transmitted infection (STI) that can cause symptoms such as urethritis, cervicitis, endometritis and pelvic inflammatory disease. In recent studies, it has been found to have a higher prevalence than gonorrhoea.4 Like gonorrhoea, M. genitalium is also evolving into a so-called STI superbug that is becoming resistant to many antibiotic treatments leading to exceedingly difficult to treat infections and threatening global public health. Macrolide antibiotics, specifically azithromycin, are the first-line treatment for the rapidly growing problem of M. genitalium STIs, but resistance to these antibiotics has increased up to 50% in several countries.1,5,6 Due to this growing antibiotic resistance problem, several global STI Management Guidelines on M. genitaliumInfections recommend complementing the use of molecular testing to detect M. genitalium with an assay capable of detecting macrolide resistance-associated mutations.2,3,7
Currently, there is not a Food & Drug Administration (FDA) cleared molecular diagnostic test for the detection of M. genitalium in the US. The SpeeDx ResistancePlus® MG assay is CE marked for sale in Europe and TGA approved for sale in Australia. The test provides valuable detection and antibiotic resistance information to clinicians in a rapid time frame. Timely detection of antibiotic resistant infections enables better treatment of the disease for patients, lessens the potential for spreading among vulnerable populations and combats antibiotic resistance.
Founded in 2009, SpeeDx is an Australian-based private company with offices in London and the US, and distributors across Europe. SpeeDx specializes in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management. Innovative real-time polymerase chain reaction (qPCR) technology has driven market-leading multiplex detection and priming strategies. Product portfolios focus on multiplex diagnostics for sexually transmitted infection (STI), antibiotic resistance markers, and respiratory disease. For more information on SpeeDx please see: https://plexpcr.com
- Read T R H, Fairley C K, Murray G L, et al. Outcomes of resistance-guided sequential treatment of Mycoplasma genitalium infections: a prospective evaluation, Clinical Infectious Diseases, ciy477, https://doi.org/10.1093/cid/ciy477
- Miller WC, Ford CA, Morris M, et al. Prevalence of chlamydial and gonococcal infections among young adults in the United States. JAMA 2004; 291:2229-2236.
- Getman D, Jiang A, O'Donnell M, Cohen S. 2016. Mycoplasma genitalium prevalence, coinfection, and macrolide antibiotic resistance frequency in a multicenter clinical study cohort in the United States. J Clin Microbiol 54:2278-2283.
- Murray GL, Bradshaw CS, Bissessor M, et al. Increasing Macrolide and Fluoroquinolone Resistance in Mycoplasma genitalium. Emerging Infectious Diseases. 2017;23(5):809-812. doi:10.3201/eid2305.161745.
- Jensen JS, Cusini M, Gomberg M, Moi H. 2016. 2016 European guideline on Mycoplasma genitalium infections. J Eur Acad Dermatol Venereol. PMID: 27505296.
- O'Neill J. The Review on Antimicrobial Resistance. May 2016:35.
NHMRC Research Fellow, Central Clinical School, Monash University
Sexual Health Physician, Melbourne Sexual Health Centre
+61 3 9341 6255
Europe, Australia, New Zealand
+61 2 9209 4170
+1 415 202 4445
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: SpeeDx Pty Ltd via Globenewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg saker fra GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra GlobeNewswire
ALLDATA Signs European Licensing Agreement with Honda25.6.2019 06:00:00 CEST | Pressemelding
ALLDATA continues to meet demand for OEM repair information on the most advanced vehicle technologies in the European market ELK GROVE, Calif., June 24, 2019 (GLOBE NEWSWIRE) -- ALLDATA Europe GmbH, an affiliate of ALLDATA LLC, an AutoZone company, has signed an agreement with Honda Motor Europe Ltd., to republish Honda repair and maintenance information for cars. The addition of Honda brings the total number of brands in ALLDATA Repair to 23. With more than 1,000 models, ALLDATA delivers the most comprehensive source of manufacturer repair procedures, instructions, and diagrams to the independent aftermarket. ALLDATA Repair is uniquely positioned to provide technicians with repair information required to complete even the most difficult repair jobs facing workshops today. Garages rely on ALLDATA Repair to provide OEM information to diagnose, maintain and repair the most innovative technologies to manufacturer standards. “With the addition of Honda, ALLDATA Repair can now serve more ve
ERYTECH Announces Immune Modulation Strategic Collaboration with SQZ Biotechnologies24.6.2019 23:30:00 CEST | Pressemelding
LYON, France and CAMBRIDGE, Mass., June 24, 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma (ERYTECH) (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells (RBCs), announced today that it has entered into an agreement with SQZ Biotechnologies (SQZ), a cell therapy company developing novel treatments in multiple therapeutic areas, to advance novel RBC-based therapeutics for immune modulation . Under the terms of the agreement, ERYTECH has granted to SQZ an exclusive worldwide license to develop antigen-specific immune modulating therapies employing RBC-based approaches. Combining SQZ’s proprietary and versatile cell engineering platform, Cell Squeeze®, with ERYTECH’s intellectual property related to RBC-based therapeutics is intended to allow for the rapid development of a broad pipeline of novel immunomodulatory products addressing multiple indications. ERYTECH is eligible to rec
Forterra Announces Leadership Appointments24.6.2019 22:24:00 CEST | Pressemelding
Construction Materials Veteran Karl H. Watson, Jr. Named Chief Executive Officer Forterra Board Member John McPherson Appointed Lead Director and Vice Chairman of the Board Company Reaffirms Full Year 2019 Outlook IRVING, Texas, June 24, 2019 (GLOBE NEWSWIRE) -- Forterra, Inc. (“Forterra” or the “Company”) (NASDAQ:FRTA), a leading manufacturer of water and drainage infrastructure pipe and products in the United States and Eastern Canada, today announced that Karl H. Watson, Jr. has been appointed Chief Executive Officer and a member of the Forterra Board of Directors. Mr. Watson succeeds Jeff Bradley, who has stepped down as CEO and a director to pursue other opportunities. Mr. Watson brings over 30 years of global experience in the construction materials industry and a track record of effectively leading through numerous business cycles and improving financial and operational results. He most recently served as Executive Vice President and Chief Operating Officer at Summit Materials,
Oxford Immunotec Appoints Patrick J. Balthrop, Sr. as Chairman24.6.2019 17:35:00 CEST | Pressemelding
OXFORD, United Kingdom and MARLBOROUGH, Mass., June 24, 2019 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company"), a global, high-growth diagnostics company, today announced that it has appointed Patrick J. Balthrop, Sr. as Chairman of its board of directors. The current Chairman, Mr. Richard A. Sandberg, will remain a member of the board. “On behalf of the Company and the board of directors I would like to thank our former Chairman, Richard Sandberg, for his service,” said Dr. Peter Wrighton-Smith, CEO of Oxford Immunotec. “In the decade that he served as Chairman, the Company has undergone a profound transformation, and Mr. Sandberg’s guidance and leadership has made an extraordinary contribution to Oxford Immunotec’s success. We look forward to continuing to benefit from his skills and his knowledge of the Company with his ongoing service as a Non-Executive Director.” “We are very pleased to have Mr. Balthrop assume the role of Chairman,” continued Dr. Wrigh
Woodbridge by Robert Mondavi Announces New Transformative Brand Positioning24.6.2019 15:50:00 CEST | Pressemelding
“From One For All” National Campaign Brings Brand’s Pioneering Spirit to the Forefront of Story and Marks a Number of Brand Firsts LODI, Calif., June 24, 2019 (GLOBE NEWSWIRE) -- Woodbridge by Robert Mondavi, the number-three wine brand in the United States* with 40 years of history dedicated to raising the standard for everyday wines in America and globally, announces a new milestone with the launch of its new national brand campaign. The “From One For All” campaign celebrates Woodbridge founder Robert Mondavi’s pivotal role in democratizing wine. It is supported by a 360-degree integrated marketing plan backed by the largest investment in the brand’s history. For the first time, Woodbridge by Robert Mondavi tells the winery’s powerful founding story and industry-changing vision through the lens of its iconic founder Robert Mondavi in the new “From One For All” marketing campaign. Celebrated for his achievements helping to establish California’s reputation for fine winemaking on a glo
Sanan IC Expands Wafer Foundry Portfolio for Power Electronics with 150mm GaN-on-Silicon Process24.6.2019 15:00:00 CEST | Pressemelding
SUNNYVALE, Calif., June 24, 2019 (GLOBE NEWSWIRE) -- SANAN INTEGRATED CIRCUIT CO., LTD. (Sanan IC), a pure-play wafer foundry with its advanced compound semiconductor technology platform, today announced the commercial release of its 150mm gallium nitride (GaN) on silicon wafer foundry services intended for the latest high voltage AC/DC and DC/AC power electronics applications in the global market. Sanan IC’s new G06P111 is a 650V enhanced-mode high-electron-mobility transistor (E-HEMT) GaN process which adds to the company’s power electronics wafer foundry portfolio of wide bandgap (WBG) compound semiconductors that includes 100mm and 150mm silicon carbide (SiC) for high voltage Schottky Barrier Diodes (SBD). Leveraging years of high volume GaN manufacturing experience by Sanan Optoelectronics Inc., its parent company, for the LED market, Sanan IC is able to complement its foundry services with in-house MOCVD growth capabilities of high voltage, low leakage GaN-on-silicon epitaxial wa